Get full access to one story every week, and to summaries of all other stories. Just create a free account

At least once a month, Bhavik Kumar, founder and CEO of Medibox, gets a panicked call. The callers are worried Indian medicine distributors, desperate to either shut down or get acquired. As the head of Medibox, a digital platform for e-marketing, e-procurement and e-distribution of medicines and healthcare products, Kumar is in a unique position. While, on the one hand, his platform helps connect distributors to pharmacies, the network he has created means that Kumar is able to help connect these beleaguered distributors to potential buyers. One way or the other, Kumar does what he can.

Ever since the inception of the Goods and Services Tax (GST) on 1 July 2017, the calls have only increased in frequency. You see, GST has been something of a death blow to India’s circuitous pharma distribution set-up. Already, around two-thirds of small pharma distributors have shut shop.

The pharmaceutical supply chain in India is chaotic at best. Consider this: A handful of players control the entire chain in the US. In India? It takes 80,000 distributors along with over 8,00,000 retailers. The relay starts at the drug manufacturer with Carrying and Forwarding Agents (C&Fs) who operate within a state and under its tax regime. They ensure the drugs reach the thousands of distributors for a service charge from pharma companies, who have corporate offices in metros. From here, without any organised or expected pattern, distributors supply semi-wholesalers who, in turn, sell to pharmacies spread across the country.

It’s a complicated process, and it comes with significant drawbacks. Medicines being inaccessible in certain geographies or expiring. Problems costly to both life and business. “Why is Lux soap available everywhere in the country but paracetamol or life-saving drugs are not? Why do Rs 3,000 crore ($414.4 million) of medicines expire each year in warehouses?” Kumar indicates that the circuitous, unorganised system is to blame.

Enter, GST.

GST, a ‘one nation-one tax’ system, has drastically altered the Indian pharmaceutical distribution landscape. With the removal of state-level taxes, the valuation of traditional drug distribution businesses has been slashed by a third on account of competition from distributors in other states as well as far-flung warehouses now being in less demand.

This would never have been possible before GST, with state-level taxes ensuring that local distributors would always have a significant pricing advantage. By breaking down tax borders, GST also did away with the need for many middlemen. In addition, it effectively legitimised online pharmacies, thereby simplifying the supply chain.

The growing demand for services like Medibox is an example of this. Sure, the 700-odd distributors using Medibox’s e-distribution platform are a small drop in the ocean of India’s 80,000 drug distributors. But they represent the start of a change.

AUTHOR

Ruhi Kandhari

Ruhi writes on the impact of healthcare policies, trends in the healthcare sector and developments on the implementation of Electronic Health Records in India. She has an M. Sc. in Development Studies from the London School of Economics.

View Full Profile

Subscribe to read this story

The Ken is the only business subscription you need. Questions?

 

Premium

  • 5 original and reported longform business stories every week
  • Access to ONLY India edition
  • Close to 250 exclusive stories every year
  • Full access to over 6 years of paywalled stories
  • Pick up to 5 premium subscriber newsletters
  • 4 original and reported longform business stories each week
  • Access to ONLY Southeast Asia edition
  • Close to 200 exclusive stories every year
  • Full access to all paywalled stories since March 2020
  • Pick up to 5 premium subscriber newsletters

Rs. 2,750 /year

$ 120 /year

India Edition
Subscribe Subscribe
Most Asked For

Borderless

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 6 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories

Rs. 4,200 /year

Subscribe
 

Echelon

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 6 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories
  • Bonus annual gift subscription
  • Priority access to all new products and features

Rs. 8,474 /year

Subscribe
Or

Questions?

What kind of subscription plans do you offer?

We have three types of subscriptions
- Premium which gives you access to either the India or the Southeast Asia edition.
- Borderless which gives you complete access to The Ken across both editions
- Echelon which gives you complete access to The Ken across both editions along with a bonus gift subscription

What do I get if I subscribe?

The Premium edition gives you access to stories in that edition along with any five subscriber-only newsletters of your choice.

The Borderless and Echelon subscription gives you complete access to The Ken across editions and unlimited access to as many newsletters as you like.

What topics do you usually write about?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics. We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

Our specialised subscriber-only newsletters are written by our expert, award-winning journalists and cover a range of topics across finance, retail, clean energy, cryptocurrency, ed-tech and many more.

How many newsletters do you have?

We are constantly adding specialised subscriber-only newsletters all the time. All of these are written by our team of award-winning journalists on a specialised topic.

You can see the list of newsletters that we publish over here.

Does a Premium subscription to your Indian edition get me access to the Southeast Asia edition? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

We recommend the Borderless or the Echelon Plan which will give you access to stories across both editions.

Do you have a mobile app?

Yes! We have a top-rated mobile app on both iOS and Android which allows you to read on-the-go and has some amazing features like the ability to bookmark stories, save on your device, dark mode, and much more. It’s really the best way to read The Ken.

Is there a free trial?

You can sign up for a free account to experience The Ken and understand our products better. We’ll send you some free stories and newsletters occasionally, and you can access our archive of previously published free stories. You can stay on the free account as long as you’d like.

The vast majority of our stories, articles and newsletters can be accessed only by a paid subscription.

Do you offer any discounts?

Sorry, no. Our journalism is funded completely by our subscribers. We believe that quality journalism comes at a price, and readers trust and pay us so that we can remain independent.

Do you offer refunds?

No. We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Just write to us at [email protected] with details. We’ll help you out.

I have a few more questions. How can I reach out to you?

Sure. Just email us at [email protected] or follow us on Twitter.